Brigatinib/Brigatinib’s primary target

Brigatinib is a novel molecule that is very effective in treating non-small cell lung cancer and certain drug-resistant cases where other ALK inhibitors have failed. The potent anticancer activity of brigatinib is attributed to its chemical structure, which contains multiple functionalities as well as phosphorus atoms that bind to target proteins.

Brigatinib exhibits its anti-cancer activity by effectively inhibiting ALK (anaplastic lymphoma kinase), insulin growth factor receptor-1, EGFR (epidermal growth factor receptor), and multiple kinases such as CD135 (also known as FLT3, fms-like tyrosine kinase 3). Its main mechanism of action is to block the binding of phosphate groups to ALK, thereby preventing the phosphorylation of other proteins related to lung cancer. Multiple studies on mice have revealed that brigatinib can not only inhibit the proliferation of various cell lines, but also effectively prevent the production of nucleophosmin and ALK fusion genes. In addition, it can inhibit various mutants such as G1202R, L1196M and so on.

In addition to the treatment of lung cancer, brigatinib also brings new hope to patients with brain diseases. The study found that at concentrations lower than 500nM, brigatinib can effectively inhibit the carcinogenic ability of cells and play a role in cases that are resistant to traditional ALK inhibitors. It is worth mentioning that although brigatinib is generally considered a safe drug, more than 10% of patients receiving standard doses reported some common side effects, such as increased blood sugar, nausea, diarrhea, cough and headache. At the same time, some rarer adverse reactions were observed in a small number of patients, including hypertension, pneumonia, interstitial lung disease/pneumonitis, and visual impairment).